Roger Soloway, MD
Andrea Duchini, MD
Rashid Khan, MD
Monica O'Donohoe, PA-C
Types of Diseases Seen
Hepatitis C, Hepatitis B, alcoholic liver disease, Non alcoholic fatty liver disease, Primary biliary cirrhosis, Hemachromatosis, Wilson's disease, drug induced hepatitis, primary sclerosing cholangitis, complications of portal hypertension, abnormal liver function tests of unknown etiology.
Types of Treatments Provided
Anti-viral treatment for hepatitis C and B. Management of portal hypertension and complications. Management of non alcoholic fatty liver disease. Liver Biopsy for diagnosis and staging of liver disease. Liver transplantation and evaluation.
Unique or New Things that UTMB Does in this Field
Studies of new therapies for viral hepatitis, non invasive evaluation of portal hypertension, development of markers for hepatic fibrosis, basic research on hepatic injury and inflammation in hepatitis.
How to Make an Appointment
The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.Currently available protocols are:
- CAP - Community Acquired Pneumonia Orderset
- Congestive Heart Failure (CHF)
- Chronic Obstructive Pulmonary Disease (COPD)
- Diabetic Ketoacidosis Adult, ICU
- General Medicine Admission
- Immunodeficiency Flow Panel
- MICU/CCU Admission Order Set
- Oral Analgesic Medicaitons
- Parenteral Opioids
- Sepsis, Adult ICU
- 111 - Stroke Alert
- 112 - Stroke Activation
- 300086 - Stroke Floor Admission
- 3000000001 - Stroke Critical care without tPA
- 300088 Stroke - Transfer from Critical care to floor
- 3004002 - Stroke Discharge
All protocols can be found in the EPIC order set section.
The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.